Overseas Trading: Shanghai Composite Plummets; Europe Booms

Stocks in Europe are overcoming a sell-off in Shanghai stocks

by Josh Selway

Published on Feb 25, 2016 at 8:53 AM
Updated on Feb 25, 2016 at 8:54 AM

Stocks in China sold off, leaving the Shanghai Composite with its lowest close since Feb. 3. Specifically, the Chinese benchmark fell 6.4%, and concerns about tighter liquidity in the market appeared to be the main driver for the sell-off, which comes as Group of 20 (G-20) leaders converge on Shanghai. Hong Kong's Hang Seng followed suit by shedding 1.6%. South Korea's Kospi, meanwhile, managed a 0.3% lead, while Japan's Nikkei posted a 1.4% win thanks to a cooling yen, though electronics heavyweight Sharp sold off on takeover chatter. 

Despite China's struggles, stocks in Europe are enjoying broad gains at midday on positive economic news and seemingly stabilizing oil prices. U.K.'s fourth-quarter domestic product (GDP) reading was upwardly revised, and, while it was last seen slightly lower, U.S. crude oil dated for April seems to have found a home atop $31 per barrel, appeasing some fear among investors. London's FTSE 100 was up 2.4% at last check, France's CAC 40 was 2.2% higher, and Germany's DAX had added 1.5%. 


160225OS


Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical  levels, and top economic stories straight to your inbox.


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.
Wall Street Reacts to Fed Decision, Trade Deal
Investors waited and reacted to the Fed decision and trade headlines
Sarepta Therapeutics Stock Eyes Best Day in 3 Years on FDA Reversal
SRPT is buzzing on the FDA's change of heart
The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.